The 14% reduction in maximum offering size suggests underwriters are adjusting demand expectations downward. Monitor for further pricing/term changes in subsequent amendments and the final IPO pricing. The company has no public market yet — first trade will set the initial valuation.
Executive Summary
Retension Pharmaceuticals filed Amendment No. 2 to its S-1 registration statement solely to update the filing fee table (Exhibit 107). The maximum aggregate offering price was reduced from $57.5 million to $49.335 million, reflecting a ~14% downsizing of the proposed IPO. No additional registration fee is due as the previously paid fee covers the reduced amount. The offering terms remain 3,300,000 shares at $11.00-$13.00 per share, with listing on Nasdaq under 'RTSN'.
Key Financial Metrics
Key Facts
- IPO size reduced: maximum aggregate offering price lowered from $57.5M to $49.335M (a ~14% reduction).
- Offering remains 3,300,000 shares at $11.00-$13.00 per share, unchanged from Amendment No. 1.
- No additional registration fee required; $4,292.15 offset claimed against previously paid $7,940.75.
- Filing is purely administrative — updates only the fee table; all other prospectus content unchanged.
- Company is an emerging growth company and smaller reporting company; seeks Nasdaq listing under RTSN.
Financial Impact
IPO size reduced by ~$8.2M (from $57.5M to $49.335M max aggregate offering price).
Risk Factors
- Downsized IPO may signal weaker investor demand or a need to lower valuation expectations.
- No revenue or financial data available in this filing — pre-revenue clinical-stage biotech risk.
- Reverse stock split effective October 2, 2026 indicates prior share price management for listing compliance.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001213900-26-107572 |
| Document: ea027691109ex-fee.htm | 0001213900-26-107572 |
| Document: 0001213900-26-107572-index-headers.html | 0001213900-26-107572 |
| Document: 0001213900-26-107572-index.html | 0001213900-26-107572 |
| Document: 0001213900-26-107572.txt | 0001213900-26-107572 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $16.55 | awaiting T+5 | — | $14.55 (−12.11%) |
Oct 16, 2026 9d ago | SC 13G | $16.33 | awaiting T+5 | — | $14.55 (−10.93%) |
Oct 16, 2026 10d ago | SC 13G | $14.07 $15.25 | ▲ +8.39% | ▲ +8.82% | $14.55 (+3.38%) |
Oct 15, 2026 11d ago | SC 13G | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.55 (+19.12%) |
Oct 14, 2026 11d ago | SC 13D | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.55 (+19.12%) |
Oct 13, 2026 12d ago | Insider Cluster | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.55 (+24.96%) |
Oct 13, 2026 12d ago | 3 | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.55 (+24.96%) |
Oct 9, 2026 16d ago | 424B4 | $11.32 $16.33 | ▲ +44.26% | ▲ +45.75% | $14.55 (+28.49%) |
Oct 9, 2026 17d ago | EFFECT | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.55 (+38.13%) |
Oct 8, 2026 17d ago | 3 | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.55 (+38.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers